Profile data is unavailable for this security.
About the company
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
- Revenue in SEK (TTM)47.29m
- Net income in SEK-53.67m
- Incorporated2007
- Employees18.00
- LocationEnzymatica AB (publ)Ideon Science Park, Scheelevagen 19LUND 223 70SwedenSWE
- Phone+46 462863100
- Websitehttps://www.enzymatica.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solasia Pharma KK | 26.58m | -76.93m | 390.72m | 24.00 | -- | 3.00 | -- | 14.70 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| PuraPharm Corp Ltd | 547.30m | -142.70m | 394.09m | 662.00 | -- | 1.91 | -- | 0.7201 | -0.2685 | -0.2685 | 1.03 | 0.3871 | 0.4374 | 1.04 | 4.21 | 614,590.60 | -11.40 | -9.20 | -34.00 | -19.70 | 53.24 | 59.52 | -26.07 | -19.33 | 0.3046 | -2.02 | 0.7349 | -- | -9.20 | -11.41 | 11.76 | -- | -13.68 | -- |
| Lexaria Bioscience Corp | 4.25m | -57.14m | 397.21m | 5.00 | -- | 5.02 | -- | 93.43 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Medexus Pharmaceuticals Inc | 1.19bn | -2.25m | 397.44m | 98.00 | -- | 1.25 | 6.77 | 0.3347 | -0.0166 | -0.0166 | 6.89 | 1.69 | 0.7131 | 2.00 | 4.93 | -- | -0.135 | -5.03 | -0.2558 | -7.77 | 52.64 | 53.26 | -0.1893 | -8.05 | 0.63 | 1.20 | 0.622 | -- | 4.59 | 34.37 | -117.53 | -- | -9.45 | -- |
| LSL Pharma Group Inc | 93.87m | -35.64m | 399.99m | -- | -- | 3.22 | -- | 4.26 | -0.056 | -0.056 | 0.1466 | 0.1489 | 0.3929 | 2.59 | 4.87 | -- | -14.92 | -- | -21.69 | -- | 19.76 | -- | -37.97 | -- | 0.4505 | -0.8465 | 0.4938 | -- | -- | -- | -- | -- | -- | -- |
| Next Science Ltd | 233.82m | -171.53m | 402.00m | -- | -- | 2.97 | -- | 1.72 | -0.1049 | -0.1049 | 0.1413 | 0.0656 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| CRUSHMETRIC Group Ltd | 9.26m | -90.04m | 402.20m | 20.00 | -- | 1.60 | -- | 43.42 | -0.0244 | -0.0244 | 0.0029 | 0.0779 | 0.0257 | 5.08 | 17.96 | -- | -25.36 | -25.22 | -30.89 | -56.66 | 72.58 | 41.64 | -985.69 | -200.76 | 0.0309 | -2.94 | 0.0814 | -- | -36.42 | -8.40 | -1,096.05 | -- | -29.47 | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 405.71m | 18.00 | -- | 4.83 | -- | 8.58 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| COSMO BIO COMPANY, LIMITED | 615.89m | 26.58m | 410.90m | 155.00 | 14.91 | 0.6836 | 11.11 | 0.6672 | 69.94 | 69.94 | 1,620.67 | 1,525.81 | 0.8484 | 6.09 | 2.87 | 61,000,000.00 | 3.80 | 5.62 | 4.54 | 6.72 | 33.82 | 37.40 | 4.48 | 6.23 | 5.15 | -- | 0.0021 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| Hin Sang Group (Interntnl) Hldng Co Ltd | 124.59m | -49.37m | 411.23m | 265.00 | -- | 1.46 | -- | 3.30 | -0.0336 | -0.0336 | 0.0848 | 0.1913 | 0.1536 | 2.34 | 8.44 | -- | -6.04 | -5.11 | -9.78 | -7.04 | 61.98 | 59.72 | -39.30 | -28.42 | 0.1287 | -1.81 | 0.6054 | -- | 13.70 | -12.83 | 25.84 | -- | -- | -- |
| Fortress Biotech Inc | 894.09m | -660.27m | 414.88m | 186.00 | -- | 1.48 | -- | 0.464 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Medico Remedies Ltd | 182.31m | 10.43m | 417.78m | -- | 40.42 | 6.34 | 29.73 | 2.29 | 0.99 | 0.99 | 17.31 | 6.31 | 1.58 | 6.10 | 3.38 | -- | 9.03 | 6.15 | 16.70 | 12.40 | 24.16 | 25.26 | 5.72 | 3.99 | 1.34 | 12.18 | 0.1332 | -- | 3.19 | 8.21 | 14.49 | 39.49 | -7.58 | -- |
Data as of Jul 05 2024. Currency figures normalised to Enzymatica AB (publ)'s reporting currency: Swedish Krona SEK
1.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 31 Mar 2023 | 2.83m | 1.63% |
| Evli Fund Management Co. Ltd.as of 31 May 2024 | 18.14k | 0.01% |
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
